Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Nov 17;3:54. doi: 10.1186/s40425-015-0097-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Li et al. 2015

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Cetuximab responders showed decreased CD163⁺ cells and IL-10 transcripts in circulating CD11b⁺CD14⁺HLA-DR^hi monocytes after cetuximab treatment. a Representative figures showing percentage of CD68⁺CD163⁺ cells in circulating CD11b⁺CD14⁺HLA-DR^hi cells from responders and non-responders during, pre- and post-neoadjuvant cetuximab treatment. b Summary data of frequency of CD163⁺ cells in CD11b⁺ CD14⁺HLA-DR^hi monocytes in the peripheral circulation pre- and post-cetuximab treatment in the total 29 HNSCC patients (left panel) and in responders (n = 10, *p < 0.05) and non-responders (n = 19) of UPCI 08–013 trial. Circulating CD11b⁺CD14⁺HLA-DR^hi monocytes were sorted from PBMC of 14 cetuximab treated patients and RNA was isolated for real time quantitative PCR analysis of IL-10 transcripts. c Summary data showing relative IL-10 expression in circulating CD11b⁺CD14⁺HLA-DR^hi monocytes pre- and post-cetuximab treatment in the total 14 HNSCC patients tested (left panel, *p < 0.05) and in responders (n = 6, *p < 0.05) and non-responders (n = 8) in the neoadjuvant cetuximab trial (right panel). The quantity of each cDNA sample was normalized by GUSB. All of the experiments were performed in triplicate. Statistical significance was determined by Wilcoxon matched-pair signed rank tests. *p < 0.05. p > 0.05 was considered to be not significant (n.s.)